Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4033.

https://doi.org/10.1182/blood-2019-124179

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT, Ameliorate Disease in Autoimmune Models, Potently Kill Human Immune Cells from Normal Donors and MS Patients, and Achieve Immune Depletion in Non-Human Primates (NHP)

Geoff O Gillard, Jennifer L Proctor, BS, Melissa L. Brooks, BS, Tahirih L Lamothe, BS, Sharon L. Hyzy, MS, Oliver Mikse, Sean McDonough, Rahul Palchaudhuri, PhD, Anjali Bhat, MS, Ganapathy N. Sarma, PhD, Prashant Bhattarai, Pranoti Sawant, MS, Bradley R Pearse, PhD, Charlotte F. Mcdonough, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2019) 134 (Supplement_1): 3208.

https://doi.org/10.1182/blood-2019-130752

Published: 2019

Journal Articles

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Cassidy Brothers, MD MSC

Blood (2019) 134 (Supplement_1): 5631.

https://doi.org/10.1182/blood-2019-125378

Published: 2019

Journal Articles

Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing

Blood (2019) 134 (Supplement_1): 4632.

https://doi.org/10.1182/blood-2019-129394

Published: 2019

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD

Blood (2018) 132 (Supplement 1): 5332.

https://doi.org/10.1182/blood-2018-99-110585

Published: 2018

Journal Articles

Impact of Pre-Transplant Rituximab on Efficacy of Revaccination of Lymphoma Patients after Autologous Hematopoietic Stem Cell Transplantation

Elaina V. Preston, PA-C,MPH, Meighan A. Palazzo, BSN MSN NP-C, Kenneth Seier, MS, Sean M Devlin, PhD, Sergio Giralt, MD, Michael Scordo, MD, Parastoo B. Dahi, MD, Matthew J Matasar, Craig H. Moskowitz, MD, Craig S. Sauter, MD, Gunjan L. Shah, MD, Miguel-Angel Perales, MD

Blood (2018) 132 (Supplement 1): 4592.

https://doi.org/10.1182/blood-2018-99-112509

Published: 2018

Journal Articles

Patient with Myeloma Who Develops Thrombotic Microangiopathy without Hemolysis

Juliana Alvarez Argote, MD

Blood (2018) 132 (Supplement 1): 5661.

https://doi.org/10.1182/blood-2018-99-117095

Published: 2018

Journal Articles

Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma

Nicole Pearl, PharmD, Andrew Lin, PharmD, BCOP, Patrick Hilden, MS, Larry W Buie, PharmD, BCOP, FASHP, Kevin Robinson, Molly Maloy, MS, Gunjan L. Shah, MD

Blood (2018) 132 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2018-99-119554

Published: 2018

Journal Articles

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

Alessandro de Moura Almeida, MD, Helma Pinchemel Cotrim, PhD, Dayanne Costa Fonseca, MD, Dora Marcia Alencar, MD, Daniela Dourado Dutra, MD, Herbert Henrique de Melo Santos, MD, Monica Botura, MD, Marco Aurelio Salvino, PhD, Maria da Gloria Bomfim Arruda, PhD

Blood (2018) 132 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2018-99-120015

Published: 2018

Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD

Blood (2017) 130 (Supplement 1): 410.

https://doi.org/10.1182/blood.V130.Suppl_1.410.410

Published: 2017

Journal Articles

AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation

Ashwin Sridharan, Carolina D. Schinke, MD, George Georgiev, Mariana Da Silva Ferreira, Kith Pradhan, PhD, Yu Xia, PhD, Maya Panjikaran, MS, Gregory Sims, Chirag Bhagat, Armin Graber, Christoph Heuck, MD, Daisy Alapat, MD, Niels Weinhold, PhD, Sarah K Johnson, PhD, Bart Barlogie, MD PhD, Gareth J. Morgan, MD PhD, Ulrich G. Steidl, MDPhD, Britta Will, PhD, Amit Verma, MD

Blood (2017) 130 (Supplement 1): 2706.

https://doi.org/10.1182/blood.V130.Suppl_1.2706.2706

Published: 2017

Journal Articles

Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2017) 130 (Supplement 1): 5215.

https://doi.org/10.1182/blood.V130.Suppl_1.5215.5215

Published: 2017

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

Novel Mutations in RASGRP1 Are Associated with Immune Dysregulation and Predispose to EBV-Induced Lymphoma

Ido Somekh, MD, Benjamin Marquardt, MSc, Yanshan Liu, PhD, Meino Rohlfs, PhD, Shirly Frizinsky, MD, Ekrem Unal, MD, Daniel Kotlarz, MD PhD, Raz Somech, MD PhD, Christoph Klein, MD PhD

Blood (2017) 130 (Supplement 1): 2287.

https://doi.org/10.1182/blood.V130.Suppl_1.2287.2287

Published: 2017

Journal Articles

EBV Reactivation Incidence and Severity in Multiple Sclerosis Patients Treated with Autologous Haematopoietic Stem Cell Transplant and Comparing with Aplastic Anaemia Treated with ATG—Single Site Experience

Blood (2017) 130 (Supplement 1): 4535.

https://doi.org/10.1182/blood.V130.Suppl_1.4535.4535

Published: 2017

Journal Articles

Post Autologous Stem Cell Transplant Light Chain Response Is a Prognostic Marker in Multiple Myeloma Patients in PR/ VGPR after Induction Therapy

Naresh Bumma, MD, Monica Peravali, MD, Jayadev Mettu, MD, Ghayathri Jeyakumar, MD, Seongho Kim, PhD, Divaya Bhutani, MD, Abhinav Deol, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Asif Alavi, MD

Blood (2017) 130 (Supplement 1): 5518.

https://doi.org/10.1182/blood.V130.Suppl_1.5518.5518

Published: 2017

Journal Articles

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

Betty Gration, MBBS, Ana Duran, MD, Naheed Mir, BSc, FRCP, FRCPath, Lisa Yuen, MPharm, PgDip, IP, Marcus Warner, MPharm, PG Dip GPP, Karen Stanley, RGN, MSc Advanced Practice, Jessica Brady, MBBCh, FRCR, George Mikhaeel, MB BCh, MSc, FRCR, Paul A Fields, MD PhD, David Wrench, MA, MBBChir, FRCPath, PhD

Blood (2017) 130 (Supplement 1): 4133.

https://doi.org/10.1182/blood.V130.Suppl_1.4133.4133

Published: 2017

NARROW

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT, Ameliorate Disease in Autoimmune Models, Potently Kill Human Immune Cells from Normal Donors and MS Patients, and Achieve Immune Depletion in Non-Human Primates (NHP)

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Impact of Pre-Transplant Rituximab on Efficacy of Revaccination of Lymphoma Patients after Autologous Hematopoietic Stem Cell Transplantation

Patient with Myeloma Who Develops Thrombotic Microangiopathy without Hemolysis

Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation

Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Novel Mutations in RASGRP1 Are Associated with Immune Dysregulation and Predispose to EBV-Induced Lymphoma

EBV Reactivation Incidence and Severity in Multiple Sclerosis Patients Treated with Autologous Haematopoietic Stem Cell Transplant and Comparing with Aplastic Anaemia Treated with ATG—Single Site Experience

Post Autologous Stem Cell Transplant Light Chain Response Is a Prognostic Marker in Multiple Myeloma Patients in PR/ VGPR after Induction Therapy

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only